- Home
- TDF vs RLMD Comparison
TDF vs RLMD Comparison
Compare TDF & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TDF | RLMD |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.0M | 319.7M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | TDF | RLMD |
|---|---|---|
| Price | $10.98 | $7.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 44.4K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $8.67 | $0.27 |
| 52 Week High | $12.20 | $7.94 |
Technical Indicators
Market Signals| Indicator | TDF | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 54.59 | 63.37 |
| Support Level | $10.12 | $3.49 |
| Resistance Level | $11.41 | $7.41 |
| Average True Range (ATR) | 0.27 | 0.44 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 73.00 | 71.24 |
Price Performance
Historical ComparisonAbout TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.